| __timestamp | ImmunityBio, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4326000 | 7461000 |
| Thursday, January 1, 2015 | 226206000 | 11960000 |
| Friday, January 1, 2016 | 94391000 | 13108000 |
| Sunday, January 1, 2017 | 53821000 | 17501000 |
| Monday, January 1, 2018 | 35463000 | 22472000 |
| Tuesday, January 1, 2019 | 46456000 | 24286000 |
| Wednesday, January 1, 2020 | 71318000 | 29689000 |
| Friday, January 1, 2021 | 135256000 | 38837000 |
| Saturday, January 1, 2022 | 102708000 | 47489000 |
| Sunday, January 1, 2023 | 129620000 | 53379000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. ImmunityBio, Inc. and Xencor, Inc. have shown contrasting approaches over the past decade. ImmunityBio's SG&A expenses have fluctuated significantly, peaking in 2015 with a staggering 2,262% increase from the previous year. In contrast, Xencor has maintained a more stable trajectory, with a gradual increase of approximately 615% from 2014 to 2023.
While ImmunityBio's expenses have been more volatile, their recent trend shows a 30% reduction from their 2015 peak, indicating improved cost management. Xencor, on the other hand, has consistently kept their expenses in check, reflecting a disciplined approach. As the biotech industry evolves, these companies' ability to manage SG&A costs will be pivotal in sustaining growth and innovation.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Xencor, Inc.
Lantheus Holdings, Inc. and Xencor, Inc.: SG&A Spending Patterns Compared
Grifols, S.A. vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Xencor, Inc.
Comparing SG&A Expenses: Veracyte, Inc. vs Xencor, Inc. Trends and Insights
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.